Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design

Abstract

Rationale and aim

Little is known about the safety and efficacy of the combination of ticagrelor and aspirin in acute ischemic stroke. This study aimed to evaluate whether the combination of ticagrelor and aspirin was superior to that of clopidogrel and aspirin in reducing the 90-day high on-treatment platelet reactivity for acute minor stroke or transient ischemic attack, especially for carriers of cytochrome P450 2C19 loss-of-function allele.

Sample size and design

This study was designed as a prospective, multicenter, randomized, open-label, active-controlled, and blind-endpoint, phase II b trial. The required sample size was 952 patients. It was registered with ClinicalTrials.gov (NCT02506140).

Study outcomes

The primary outcome was the proportion of patients with high on-treatment platelet reactivity at 90 days. High on-treatment platelet reactivity is defined as the P2Y12 reaction unit >208 measured using the VerifyNow P2Y12 assay.

Conclusion

The Platelet Reactivity in Acute Non-disabling Cerebrovascular Events study explored whether ticagrelor combined with aspirin could reduce further the proportion of patients with high on-treatment platelet reactivity at 90 days after acute minor stroke or transient ischemic attack compared with clopidogrel and aspirin.

Keywords

Clopidogrel minor stroke platelet reactivity protocol transient ischemic attack ticagrelor

Get full access to this article

View all access options for this article.

References

Amarenco

Lavallee

Labreuche

. One-year risk of stroke after transient ischemic attack or minor stroke. New Engl J Med 2016; 374: 1533–1542.

Wang

Zhao

. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New Engl J Med 2013; 369: 11–19.

Wang

DGL

Dong

Hao

. Dual antiplatelet therapy may increase the risk of nonintracranial haemorrhage in patients with minor strokes: a subgroup analysis of the chance trial. Stroke Vascu Neurol 2016; 1: e000008.

Wang

Zhao

Lin

. Association between cyp2c19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 2016; 316: 70–78.

Scott

Sangkuhl

Gardner

. Clinical pharmacogenetics implementation consortium guidelines for cytochrome p450-2c19 (cyp2c19) genotype and clopidogrel therapy. Clin Pharmacol Therapeut 2011; 90: 328–332.

Brilakis

Patel

Banerjee

. Medical management after coronary stent implantation: a review. JAMA 2013; 310: 189–198.

Wallentin

James

Storey

. Effect of cyp2c19 and abcb1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the plato trial. Lancet 2010; 376: 1320–1328.

Tantry

Bonello

Aradi

. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261–2273.

Stone

Witzenbichler

Weisz

. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (adapt-des): a prospective multicentre registry study. Lancet 2013; 382: 614–623.

10.

Nagashima

Tsukahara

Morita

. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome p450 2c19 phenotypes. J Cardiol 2013; 62: 158–164.

11.

Wang

Zhao

Jiang

. Prevalence, knowledge, and treatment of transient ischemic attacks in china. Neurology 2015; 84: 2354–2361.

12.

Kleindorfer

Panagos

Pancioli

. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005; 36: 720–723.

13.

Johnston

Gress

Browner

Sidney

. Short-term prognosis after emergency department diagnosis of tia. JAMA 2000; 284: 2901–2906.

14.

Kernan

Ovbiagele

Black

. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2014; 45: 2160–2236.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.22 MB